samedan logo
 
 
 
spacer
home > pmps > summer 2020 > nutraceuticals to see a post-covid-19 immunity boom
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Nutraceuticals to See a Post-COVID-19 Immunity Boom

The economic impact caused by COVID-19 has been felt globally. With non-essential businesses temporarily closing down and consumers being more conservative with their money than ever before, spending is at an all-time low. However, according to data from Euromonitorís national stock-out reports, it is clear that demand has been growing in the nutraceuticals space, and in particular, for immunity formulations.

Even prior to the COVID-19 outbreak, the demand for immunity products was on an upwards trend. More specifically, consumer awareness of the health benefits of vitamins and other nutrients was on the rise. It is fair to say that the COVID-19 outbreak has highlighted just how important a strong and healthy immune system is, as well as the nutraceutical products that can help strengthen immunity. Prior to the pandemic, the demand for immunity products typically peaked during the winter months when mild illnesses and infections were most common.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dominique Baum, Managing Director of AYANDA, brings over 25 years of experience in management positions of leading pharmaceutical companies in Europe and Asia. She started her professional career in marketing, which sharpened her focus for market trends and product innovation, followed by being responsible for running large commercial operations at Solvay, Abbott, and Sandoz. Dominique holds a PhD in Nutrition Science from the University of Bonn, Germany.
spacer
Dominique Baum
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

- The biotech companies 3P Biopharmaceuticals and Toleranzia collaborate for that MG treatment - MG is an orphan disease which has a major unmet medical need and a large market potential - The drug candidate,TOL2, has already achieved several positive preclinical results
More info >>

White Papers

RSSL introduces same-day mycoplasma testing service in UK

RSSL

Reading Scientific Services Ltd (RSSL), a leading provider of scientific and technical solutions to the global biopharmaceutical, pharmaceutical, and biopharmaceutical sectors, has introduced the United Kingdomís first same-day mycoplasma testing service for manufacturers of biologic medicines.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement